Interesting TGTX Put And Call Options For March 20th

For TG Therapeutics (TGTX, $30.60), the $30 put is bidding $2.10, which equates to a net purchase basis of $27.90 if sold-to-open and represents ~2% out-of-the-money; analytics show a 60% chance it expires worthless, producing a 7.00% cash-return (40.58% annualized) YieldBoost. On the call side, the $32 covered call bids $2.50; if stock is bought at $30.60 and called at the March 20 expiration, total return would be 12.75%, the strike is ~5% OTM and the chance it expires worthless is 48%, producing an 8.17% (47.37% annualized) YieldBoost. Implied vols are elevated (put IV 79%, call IV 78%) versus a trailing-12M realized volatility of 51%, making these option-yield strategies attractive to income-oriented or volatility-focused traders but caution warranted given high IV and biotech company risk.

Analysis

Market structure: Option sellers and cash-rich investors win in the near term—selling the $30 put nets $2.10 (effective basis $27.90) and selling the $32 covered call yields 12.75% to March 20. Buyers of short-dated call/put exposure lose if IV (78–79%) mean-reverts to realized vol (~51%) absent a binary event; this elevated IV signals demand for hedging or speculation and limited willingness to hold outright equity at current prices.

Risk assessment: Tail risks are binary clinical/regulatory outcomes or emergency financing that could swing TGTX ±50% inside weeks; immediate (days) risk centers on assignment and margin, short-term (weeks) risk is IV spikes/compression around news, long-term (quarters) depends on cash runway and commercial prospects. Hidden dependencies include thin option liquidity, retail gamma concentration, and the potential for forced buying/selling by option dealers; catalysts to watch are any scheduled readouts, FDA correspondence, or financing windows in the next 30–120 days.

Trade implications: For income-biased allocations, prefer defined-risk premium sales: cash‑secured puts at $30 size 1–3% portfolio or put-credit spreads (sell $30 / buy $25) to cap downside; covered-call sellers may buy stock at $30.60 and sell $32 March for a 12.75% capped return but limit position size. If you prefer volatility, sell near-dated calls/puts (short gamma) only if no known binary in 45 days and hedge with further-dated long calls or protective puts.

Contrarian angles: Consensus underestimates that IV can compress quickly absent a clinical event—selling premium is likely profitable but fraught if a surprise occurs; the 60%/48% expiration odds are model outputs that mask jump risk. Historical biotech parallels show large one-day moves on news, so size trades small (≤3% each) and require hard stop-losses or bought protection to avoid ruin from a single outcome.

Key Decisions for Investors

• Establish a cash‑secured put position: sell TGTX Mar 20 $30 put (collect $2.10) sized to 1–3% of portfolio; target effective entry at $27.90, set buy‑to‑close if TGTX < $26 (limit loss) or IV > 110%.
• If willing to own equity, buy TGTX at market (~$30.60) and sell the Mar 20 $32 call (collect $2.50) for a 12.75% return to expiry; cap position to 1–2% portfolio and buy a protective $28 put if downside risk >10% is unacceptable.
• Prefer defined-risk premium-selling vs naked exposure: sell $30/$25 put-credit spread instead of naked puts to cap max loss; size 1–2% and close if share price falls >15% or a binary event is announced within 45 days.
• Do not sell short-dated uncovered straddles around any confirmed clinical/FDA announcement; if no announced binary in the next 45 days, consider writing near-dated premium and buying longer-dated calls to hedge directional jump risk.
• Monitor (daily for 30 days) SEC filings, clinical calendar, and short interest—exit or hedge if company files for financing or a readout is scheduled within 30–120 days, as these increase jump risk materially.